Recent Material Events - Genitope Cp (GTOP)

Filing Date	Description
2008-08-12	If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) ...
2008-06-10	On June 4, 2008, Genitope Corporation (“Genitope” or the “Company”) received a staff deficiency letter from The Nasdaq Stock Market (“Nasdaq”) indicating that, for 30 consecutive trading days, the Company’s common s ...
2008-05-28	On May 21, 2008, Genitope Corporation (“Genitope” or the “Company”) received a staff determination letter from The Nasdaq Stock Market (“Nasdaq”) indicating that, as a result of the Company’s failure to timely file ...
2008-05-23	On May 20, 2008, the board of directors (the “Board”) of Genitope Corporation (“Genitope” or the “Company”) concluded that the carrying amounts of the Company’s long-lived assets were not recoverable and that a mate ...
2008-05-13	If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) ...
2008-04-02	On March 27, 2008, Genitope Corporation (“Genitope” or the “Company”) provided a notice under the federal Worker Adjustment and Retraining Notification Act (the “WARN Act”) to the following six executive officers that ea ...
2008-03-31	33 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations ...
2008-03-14	On March 6, 2008, Genitope Corporation (“Genitope” or the “Company”) received a staff deficiency letter from The Nasdaq Stock Market (“Nasdaq”) indicating that, as a result of the resignation of Stanford C. Finney from t ...
2008-03-12	On March 10, 2008, Genitope Corporation issued a press release announcing the suspension of the development of MyVax personalized immunotherapy and a press release announcing the adjournment of its upcoming special meeting of stockholders. Copies of ...
2008-02-12	On February 7, 2008, Genitope Corporation (“Genitope” or the “Company”) received a staff deficiency letter from The Nasdaq Stock Market (“Nasdaq”) indicating that, for the last 30 consecutive days, the bid price for Geni ...